Application of Ectoin Containing Lozenges (EHT02) in Patients With Acute, Viral Pharyngitis.
Launched by BITOP AG · May 7, 2019
Trial Information
Current as of June 17, 2025
Completed
Keywords
ClinConnect Summary
The current non-interventional study aims to investigate the efficacy and tolerability of Ectoin Lozenges Honey Lemon in patients suffering from acute viral pharyngitis. Participants receive treatments as part of routine medical care, and participants can choose one of two treatment options: a) Ectoin Lozenges Honey Lemon or b) lozenges containing hyaluronic acid and icelandic moss.
Efficacy will be studied by documentation of the following symptoms:
* pain on swallowing
* hoarseness
* urge to cough
* dry mouth and throat
* redness of oropharynx and larynx
* sore throat
* impairment of fr...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients with acute viral pharyngitis
- Exclusion Criteria:
- • patients with known intolerance to one of the substances used
- • Pregnancy
- • Surgical Procedures in the mouth and throat region prior to the study
- • Bacterial Pharyngitis
- • symptoms in the throat since more than 5 days
- • Contraindications according to the instructions for use
About Bitop Ag
Bitop AG is a biopharmaceutical company focused on the development and commercialization of innovative therapeutic solutions for dermatological and infectious diseases. With a commitment to advancing healthcare through cutting-edge research, Bitop AG specializes in the formulation of novel compounds and the optimization of existing treatments. The company leverages its expertise in pharmacology and biotechnology to conduct rigorous clinical trials, ensuring safety and efficacy while addressing unmet medical needs. Bitop AG is dedicated to improving patient outcomes and enhancing therapeutic options through its collaborative approach and state-of-the-art technology.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dortmund, , Germany
Patients applied
Trial Officials
Andreas Bilstein, Dr
Study Director
CSO
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials